|

Individual Patient TCR-Transduced PBL Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • National Cancer Institute (NCI)2

Indications

  • Cancer2
  • Leukemia, Lymphocytic, Acute1
  • Nonlymphoblastic Leukemia, Acute1
  • Hematopoetic Myelodysplasia1
  • Dysmyelopoietic Syndromes1

Bethesda, Maryland2 trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 2
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.